Welcome to our dedicated page for Jasper Therapeutics news (Ticker: JSPR), a resource for investors and traders seeking the latest updates and insights on Jasper Therapeutics stock.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) is a clinical-stage biotechnology company dedicated to advancing safer and more effective conditioning agents and stem cell engineering to expand the usage of hematopoietic stem cell transplants and gene therapies. Jasper’s primary focus is the clinical development of its lead compound, JSP191, a conditioning antibody designed to clear hematopoietic stem cells from the bone marrow of patients undergoing stem cell transplants. This innovative approach is aimed at reducing the risks associated with current conditioning regimens, thereby making stem cell transplants and gene therapies more accessible and safer for patients.
Jasper Therapeutics is at the forefront of developing novel therapies that target CD117, aiming to address several critical needs in the treatment of mast cell-driven diseases. Recent developments include the ongoing research and presentations related to their compound Briquilimab. These studies demonstrate promising results in preventing passive systemic anaphylaxis and allergic asthma in animal models, indicating potential applications in human allergic conditions.
In recent corporate developments, Jasper announced the fiscal quarter and year-end results for December 31, 2023, highlighting key advancements and strategic growth initiatives. The company also reported the inducement equity incentive plan aimed at attracting and retaining skilled employees, crucial for maintaining its innovative edge.
Jasper Therapeutics is continually building strategic partnerships and collaborations to support its research and development efforts. The company is committed to pushing the boundaries of biotechnology to improve patient outcomes and make curative therapies more broadly available.
For the latest updates, presentations, and financial information, investors and stakeholders are encouraged to contact Joyce Allaire, Alex Gray, or Lauren Walker for further details.
Jasper Therapeutics (Nasdaq: JSPR) presented updated clinical data from its Phase 1b/2a BEACON study and four preclinical studies for briquilimab at the AAAAI 2025 Annual Meeting. The latest data, with a cut-off date of January 31, 2025, includes one month of additional dosing and follow-up from 49 participants.
The study shows that briquilimab continues to demonstrate favorable safety profile in treating chronic spontaneous urticaria (CSU), with no additional adverse events related to c-Kit blockade. The treatment resulted in rapid and deep clinical responses in omalizumab-experienced patients with moderate to severe CSU.
Based on these positive results, Jasper plans to advance briquilimab into a Phase 2b operationally adaptive study in the second half of 2025. The company expects to report additional clinical data from approximately 70 patients treated with briquilimab doses of 180mg or higher by mid-year 2025, which will inform the final dose selection for the Phase 2b study.
Jasper Therapeutics (Nasdaq: JSPR) has announced a late-breaking oral presentation of briquilimab data from their Phase 1b/2a BEACON study in chronic spontaneous urticaria (CSU) at the upcoming 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando.
The presentation, scheduled for March 8, 2025, at 1 p.m. PST, will showcase data previously disclosed on January 8th, 2025, demonstrating briquilimab's impact on CSU patients. The abstract titled 'Briquilimab demonstrates rapid, clinically meaningful reduction in disease activity in adults with chronic spontaneous urticaria (CSU): Results from a Phase 1b/2a study' will be featured in the Late Breaking Research: Session 2.
Briquilimab is a novel antibody therapy targeting c-Kit, developed to address mast cell driven diseases including CSU, chronic inducible urticaria (CIndU), and asthma.
Jasper Therapeutics (JSPR) reported its Q4 and full-year 2024 financial results, highlighting significant progress in clinical trials for briquilimab, their novel antibody therapy. The company reported positive data from two key studies: the BEACON study in chronic spontaneous urticaria (CSU) and the SPOTLIGHT study in chronic inducible urticaria (CIndU).
Key clinical achievements include rapid and deep response profiles in urticaria patients, with weekly score improvements exceeding 25 points in doses ≥120mg. In the SPOTLIGHT study, 93% of participants achieved clinical response, with 83% experiencing complete response in the 120mg dose cohort.
Financial results show $71.6 million in cash and equivalents as of December 31, 2024. The company reported Q4 R&D expenses of $19.8 million, G&A expenses of $5.5 million, and a net loss of $24.3 million ($1.62 per share). Full-year 2024 resulted in a net loss of $71.3 million ($4.89 per share).
Jasper Therapeutics (Nasdaq: JSPR), a clinical stage biotech company developing briquilimab, announced its participation in three major investor conferences this March. The company, which focuses on developing novel antibody therapy targeting c-Kit (CD117) for mast cell driven diseases including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, will present at:
- TD Cowen 45th Annual Healthcare Conference (March 3-5, 2025) with presentation on March 3 at 1:20 p.m. EST
- Barclays 27th Annual Global Healthcare Conference (March 11-13, 2025)
- H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025 at 12:30 p.m. EST
Live webcasts will be available on Jasper's Investor Relations website with 30-day replay access.
Jasper Therapeutics (Nasdaq: JSPR) has announced multiple presentations of data for its novel antibody therapy briquilimab at the upcoming AAAAI 2025 Annual Meeting in San Diego. The presentations include five posters and one oral session, scheduled for February 28 - March 3, 2025.
The presentations will feature additional follow-up data from the Phase 1b/2a BEACON trial evaluating briquilimab in chronic spontaneous urticaria (CSU), expanding on preliminary data disclosed on January 8th, 2025. The research focuses on briquilimab's targeting of c-Kit (CD117) for treating mast cell driven diseases including CSU, chronic inducible urticaria (CIndU), and asthma.
The presentations will cover various aspects of briquilimab's mechanism of action, including its ability to deplete mast cells across multiple tissues, inhibit stem cell factor signaling, and its effectiveness in dermatitis mouse models.
Jasper Therapeutics (Nasdaq: JSPR) has announced its participation in the upcoming Oppenheimer Healthcare Life Sciences Conference, scheduled for February 11-12, 2025. The company will present in a fireside chat format on Tuesday, February 11, 2025, at 3:20 p.m. EST.
Jasper is a clinical stage biotechnology company developing briquilimab, a novel antibody therapy targeting c-Kit (CD117). The therapy aims to address mast cell driven diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and asthma.
The presentation will be available via live webcast on Jasper's Investor Relations website under the News & Events – Events page. An archived version will remain accessible for 30 days following the live broadcast.
Jasper Therapeutics (JSPR) reported positive preliminary data from its BEACON Phase 1b/2a study of briquilimab in treating Chronic Spontaneous Urticaria (CSU). The study showed significant clinical responses across multiple dosing cohorts, with the 240mg single-dose group achieving a mean UAS7 change of -26.6 from baseline at 8 weeks.
Key highlights include 100% Complete Response (UAS7 = 0) in the 240mg single-dose cohort (N=3) at 8 weeks, with 66% maintaining Well Controlled disease at 12 weeks. Multiple dosing regimens ≥120mg demonstrated UAS7 changes exceeding -25 points. The drug showed rapid onset of action, with responses observed as early as 1-week post-first dose.
Briquilimab demonstrated a favorable safety profile with no dose-limiting toxicities. Based on these results, Jasper plans to commence a CSU registrational program with a Phase 2b study in the second half of 2025.
Jasper Therapeutics (Nasdaq: JSPR), a clinical-stage biotechnology company, will host a webinar on January 8, 2025, at 8am EST to present preliminary data from the BEACON study of briquilimab in Chronic Spontaneous Urticaria (CSU). This virtual event will feature remarks from Thomas B. Casale, M.D., Professor of Medicine and Pediatrics at the University of South Florida Morsani College of Medicine, who is the lead US investigator in the BEACON study. Briquilimab is a novel antibody therapy targeting c-Kit (CD117) and aims to address mast cell-driven diseases such as CSU, chronic inducible urticaria (CIndU), and asthma.
For those interested in attending, the registration details are as follows:
- Date: Wednesday, January 8, 2025
- Time: 8:00am EST
- Registration: Click Here
Jasper Therapeutics (Nasdaq: JSPR) has announced the first patient dosing in its Phase 1b/2a ETESIAN clinical study evaluating briquilimab in allergic asthma. The study will test a single 180mg subcutaneous dose of briquilimab in approximately 30 patients across up to 7 sites in Canada. This marks Jasper's third clinical program for briquilimab in inflammatory diseases driven by mast cell activity. The double-blind, placebo-controlled challenge study aims to demonstrate proof-of-concept in asthma, with initial data expected in the second half of 2025. Key assessments will include early and late asthmatic response, airway hyperresponsiveness, and mast cell depletion and recovery.
Jasper Therapeutics (Nasdaq: JSPR), a clinical stage biotech company developing briquilimab, announces its participation in three upcoming investor conferences. The company will present at the Stifel 2024 Healthcare Conference (Nov 18-19) with a fireside chat on Nov 18 at 9:45 AM ET, the Jefferies London Healthcare Conference (Nov 19-21), and the 7th Annual Evercore ISI HealthCONx Conference (Dec 3-5) with a fireside chat on Dec 3 at 3:25 PM ET. Briquilimab is a novel antibody therapy targeting c-Kit (CD117) for mast cell driven diseases including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.
FAQ
What is the current stock price of Jasper Therapeutics (JSPR)?
What is the market cap of Jasper Therapeutics (JSPR)?
What is Jasper Therapeutics' main focus?
What is JSP191?
What recent developments has Jasper Therapeutics announced?
What are the key applications of Briquilimab?
How does Jasper Therapeutics support its research efforts?
How can investors get more information about Jasper Therapeutics?
What is the role of CD117 in Jasper Therapeutics' research?
Where can I find Jasper Therapeutics' financial reports?
What is the goal of Jasper Therapeutics' equity incentive plan?
What diseases is Jasper Therapeutics targeting with its therapies?
